The launch of Inqovi, also known as decitabine and cedazuridine, marks a significant development in the treatment of myelodysplastic syndromes (MDS). Developed by Astex Pharmaceuticals, a subsidiary of Otsuka, Inqovi is an oral combination therapy approved by the U.S. Food and Drug Administration (FDA) for adult patients with these pre-leukemic conditions [1].
When did Inqovi become available?
Inqovi received FDA approval on September 15, 2020, making it available to patients shortly thereafter [1].
What is Inqovi used for?
Inqovi is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with all French-American-British (FAB) classifications, and chronic myelomonocytic leukemia (CMML) [1].
How does Inqovi work?
Inqovi combines decitabine, a DNA methyltransferase inhibitor, with cedazuridine, a cytidine deaminase inhibitor. Cedazuridine helps to increase the bioavailability of oral decitabine by inhibiting its breakdown in the gastrointestinal tract and liver. This allows for consistent and predictable plasma concentrations of decitabine, which then works to hypomethylate DNA and reactivate tumor suppressor genes [1].
What are the key benefits of Inqovi?
The primary benefit of Inqovi is its oral administration, offering a convenient alternative to intravenous (IV) decitabine, which requires frequent hospital visits for infusions [2]. This oral formulation can improve patient quality of life and reduce the burden of treatment [2].
What are the potential side effects of Inqovi?
Common side effects reported in clinical trials for Inqovi include neutropenia, thrombocytopenia, leukopenia, anemia, diarrhea, and nausea [1]. Patients should discuss potential side effects and their management with their healthcare provider.
How does Inqovi compare to other MDS treatments?
Inqovi offers an oral option for MDS patients, distinguishing it from IV decitabine formulations. Other treatment options for MDS may include hypomethylating agents like azacitidine (oral or IV), lenalidomide (for specific MDS subtypes), and stem cell transplantation, depending on the patient's risk stratification and disease characteristics [3].
What is the patent and exclusivity situation for Inqovi?
Information regarding Inqovi's patent and exclusivity details can be found on DrugPatentWatch.com. Patent expirations and any associated exclusivity periods are crucial for understanding the drug's market life and the potential for generic or biosimilar competition [4].
Where can I find more information about Inqovi?
More detailed information about Inqovi, including prescribing information and clinical trial data, can be found on the manufacturer's website and through healthcare professional resources. DrugPatentWatch.com also provides data on drug patents and regulatory exclusivity [4].
What are myelodysplastic syndromes (MDS)?
Myelodysplastic syndromes are a group of blood cancers characterized by ineffective production of healthy blood cells by the bone marrow. This can lead to low blood counts, increasing the risk of infection, anemia, and bleeding. MDS can sometimes progress to acute myeloid leukemia (AML) [3].
What is the prognosis for patients treated with Inqovi?
The prognosis for patients treated with Inqovi depends on various factors, including the specific subtype of MDS, the patient's overall health, and their response to treatment. Clinical trials have shown efficacy in improving blood counts and potentially delaying progression to AML [1].
Who manufactures Inqovi?
Inqovi is manufactured by Astex Pharmaceuticals, a Otsuka company [1].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/fda-approves-inqovi-decitabine-and-cedazuridine-treat-myelodysplastic-syndromes
[2] https://www.drugpatentwatch.com/drug/inqovi
[3] https://www.cancer.org/cancer/types/myelodysplastic-syndromes.html
[4] https://www.drugpatentwatch.com/